Aligos Therapeutics, Inc. (NASDAQ:ALGS) Receives $41.50 Average Price Target from Analysts

Aligos Therapeutics, Inc. (NASDAQ:ALGS) has been assigned an average rating of “Moderate Buy” from the five research firms that are covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell rating, three have issued a buy rating and one has issued a strong buy rating on the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $41.50.

ALGS has been the subject of a number of recent research reports. UBS Group initiated coverage on Aligos Therapeutics in a research note on Wednesday, January 7th. They issued a “buy” rating and a $20.00 target price for the company. Wall Street Zen lowered shares of Aligos Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 7th. HC Wainwright restated a “buy” rating and set a $50.00 price objective on shares of Aligos Therapeutics in a research report on Wednesday, March 11th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Aligos Therapeutics in a research note on Wednesday, January 21st. Finally, Westpark Capital assumed coverage on shares of Aligos Therapeutics in a report on Thursday, March 26th. They issued a “buy” rating and a $48.00 target price on the stock.

Aligos Therapeutics Price Performance

Shares of Aligos Therapeutics stock opened at $7.74 on Thursday. The stock’s 50 day simple moving average is $7.26 and its 200-day simple moving average is $8.64. The stock has a market cap of $47.91 million, a P/E ratio of -0.90 and a beta of 2.62. Aligos Therapeutics has a 1-year low of $3.76 and a 1-year high of $13.69.

Aligos Therapeutics (NASDAQ:ALGS) last posted its quarterly earnings results on Thursday, March 5th. The company reported ($1.91) EPS for the quarter, beating the consensus estimate of ($2.09) by $0.18. The firm had revenue of $0.17 million during the quarter, compared to analysts’ expectations of $0.27 million. Aligos Therapeutics had a negative return on equity of 28.16% and a negative net margin of 1,106.72%. As a group, research analysts expect that Aligos Therapeutics will post -10.36 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in ALGS. Rockefeller Capital Management L.P. grew its position in Aligos Therapeutics by 900.0% in the fourth quarter. Rockefeller Capital Management L.P. now owns 10,000 shares of the company’s stock worth $93,000 after acquiring an additional 9,000 shares during the period. NorthCrest Asset Manangement LLC purchased a new stake in Aligos Therapeutics in the third quarter valued at $98,000. Susquehanna International Group LLP acquired a new position in shares of Aligos Therapeutics in the 3rd quarter valued at $99,000. XTX Topco Ltd acquired a new position in shares of Aligos Therapeutics in the 2nd quarter valued at $100,000. Finally, HRT Financial LP purchased a new position in shares of Aligos Therapeutics during the 4th quarter worth $106,000. 60.43% of the stock is currently owned by institutional investors and hedge funds.

Aligos Therapeutics Company Profile

Aligos Therapeutics, Inc is a clinical‐stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics for chronic viral infections. The company leverages proprietary nucleic acid chemistry and small‐molecule discovery platforms to create therapies aimed at reducing viral replication, lowering antigen levels and restoring host immune function. Its pipeline includes both oligonucleotide conjugates and orally administered small molecules designed to address the root causes of persistent infections.

Founded in 2014 and headquartered in South San Francisco, California, Aligos advances its programs through strategic collaborations with academic institutions, research hospitals and industry partners.